Form 4: AtriCure Chief Legal Officer Reports Stock Transactions

Karl S. Dahlquist, Chief Legal Officer of AtriCure, Inc., reports acquisition and disposal of common stock related to restricted stock and performance share awards.

Summary

• On March 1, 2025, Karl S. Dahlquist, Chief Legal Officer of AtriCure, Inc., reported transactions involving AtriCure's common stock.
• Dahlquist acquired 19,359 shares through a Restricted Stock Award under the 2023 Stock Incentive Plan, vesting in three annual installments.
• He also acquired 6,579 shares from the vesting and release of a Performance Share Award under the same plan, meeting company performance goals and service period requirements.
• Additionally, Dahlquist disposed of 9,870 shares to cover tax withholding obligations related to the vesting of previous stock awards at a price of $38.74 per share.
• Following these transactions, Dahlquist beneficially owns 67,729 shares of AtriCure common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document primarily reports routine stock transactions related to executive compensation. The vesting of performance shares is a slightly positive signal.

Positives

• The vesting of restricted stock and performance share awards suggests that the company is meeting its performance goals, which is a positive indicator.

Negatives

• The disposal of shares to cover tax obligations could be interpreted as a slightly negative signal, although it is a common practice.

Risks

• There are no specific risks mentioned in this document, but it's important to monitor insider transactions for any potential red flags.

Future Outlook

The document does not contain any specific forward-looking statements.

Industry Context

Insider trading activity is always closely watched in the medical device industry, as it can provide insights into management's confidence in the company's future performance. This filing is a routine disclosure of stock transactions related to equity compensation.

Comparison to Industry Standards

• Stock awards are a common form of compensation in the medical device industry, used to align management's interests with those of shareholders.
• Companies like Medtronic, Boston Scientific, and Abbott also utilize stock incentive plans to reward and retain key employees.
• The vesting schedules and performance metrics associated with these awards are typically aligned with industry best practices.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
• However, the vesting of performance shares could indirectly benefit shareholders if it reflects strong company performance.

Key Dates

Keywords

AtriCure, Stock Incentive Plan, Restricted Stock Award, Performance Share Award, Insider Trading, Form 4, Dahlquist, ATRC, Chief Legal Officer, Beneficial Ownership